Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart

Life Sciences

Volumn 83, Issue 17-18, 2008, Pages 613-619

  Liepinsh, Edgars ^a   Vilskersts, Reinis ^a   Skapare, Elina ^a   Svalbe, Baiba ^a   Kuka, Janis ^a   Cirule, Helena ^a   Pugovics, Osvalds ^a   Kalvinsh, Ivars ^a   Dambrova, Maija ^a  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

Cardiac energy metabolism; Carnitine; Glucose uptake; Mildronate

Indexed keywords

C PEPTIDE; CARNITINE; GLUCOSE TRANSPORTER 4; HEXOKINASE; INSULIN RECEPTOR KINASE; MILDRONATE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; UPREGULATION;

ANIMALS; BETAINE; C-PEPTIDE; CARNITINE; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HEART; HEXOKINASE; MALE; METHYLHYDRAZINES; MICE; MICE, INBRED ICR; MYOCARDIUM; RNA, MESSENGER; UP-REGULATION;

EID: 53249098300     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.08.008     Document Type: Article

References (29)

1. Ashrafian H., Frenneaux M.P., and Opie L.H. Metabolic mechanisms in heart failure. Circulation 116 4 (2007) 434-448
2. Asaka N., Muranaka Y., Kirimoto T., and Miyake H. Cardioprotective profile of MET-88 an inhibitor of carnitine synthesis and insulin during hypoxia in isolated perfused rat hearts. Fundamental and Clinical Pharmacology 12 2 (1998) 158-163
3. Benecke H., Flier J.S., Rosenthal N., Siddle K., Klein H.H., and Moller D.E. Muscle-specific expression of human insulin receptor in transgenic mice. Diabetes 42 1 (1993) 206-212
4. Broderick T.L., Christos S.C., Wolf B.A., DiDomenico D., Shug A.L., and Paulson D.J. Fatty acid oxidation and cardiac function in the sodium pivalate model of secondary carnitine deficiency. Metabolism 44 4 (1995) 499-505
5. Dambrova M., Liepinsh E., and Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovascular Medicine 12 6 (2002) 275-279
6. Degrace P., Demizieux L., Du Z.Y., Gresti J., Caverot L., Djaouti L., Jourdan T., Moindrot B., Guilland J.C., Hocquette J.F., and Clouet P. Regulation of lipid flux between liver and adipose tissue during transient hepatic steatosis in carnitine-depleted rats. Journal of Biological Chemistry 282 29 (2007) 20816-20826
7. Degrace P., Demizieux L., Gresti J., Tsoko M., Andre A., Demaison L., and Clouet P. Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat. Molecular and Cellular Biochemistry 258 1-2 (2004) 171-182
8. Foster D.W. The role of the carnitine system in human metabolism. Annals of the New York Academy of Sciences 1033 (2004) 1-16
9. Fragasso G. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure. International Journlal of Clinical Practice 61 4 (2007) 603-610
10. Fueger P.T., Bracy D.P., Malabanan C.M., Pencek R.R., Granner D.K., and Wasserman D.H. Hexokinase II overexpression improves exercise-stimulated but not insulin-stimulated muscle glucose uptake in high-fat-fed C57BL/6J mice. Diabetes 53 2 (2004) 306-314
11. Hansen P.A., Gulve E.A., Marshall B.A., Gao J., Pessin J.E., Holloszy J.O., and Mueckler M. Skeletal muscle glucose transport and metabolism are enhanced in transgenic mice overexpressing the Glut4 glucose transporter. Journal of Biological Chemistry 270 4 (1995) 1679-1684
12. Hayashi Y., Kirimoto T., Asaka N., Nakano M., Tajima K., Miyake H., and Matsuura N. Beneficial effects of MET-88 a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. European Journal of Pharmacology 395 3 (2000) 217-224
13. Hayashi Y., Muranaka Y., Kirimoto T., Asaka N., Miyake H., and Matsuura N. Effects of MET-88 a gamma-butyrobetaine hydroxylase inhibitor on tissue carnitine and lipid levels in rats. Biological & Pharmaceutical Bulletin 23 6 (2000) 770-773
14. Jonassen A.K., Sack M.N., Mjøs O.D., and Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circulation Research 89 12 (2001) 1191-1198
15. Kamalesh M. Heart failure in diabetes and related conditions. Journal of Cardiac Failure 13 10 (2007) 861-873
16. Kirimoto T., Nobori K., Asaka N., Muranaka Y., Tajima K., and Miyake H. Beneficial effect of MET-88 a gamma-butyrobetaine hydroxylase inhibitor on energy metabolism in ischemic dog hearts. Archives Internationales de Pharmacodynamie et de Therapie 331 2 (1996) 163-178
17. Lam A., and Lopaschuk G.D. Anti-anginal effects of partial fatty acid oxidation inhibitors. Current Opinion in Pharmacology 7 2 (2007) 179-185
18. Liepinsh E., Vilskersts R., Loca D., Kirjanova O., Pugovichs O., Kalvinsh I., and Dambrova M. Mildronate an inhibitor of carnitine biosynthesis induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. Journal of Cardiovascular Pharmacology 48 6 (2006) 314-319
19. Lopaschuk G.D., Spafford M.A., Davies N.J., and Wall S.R. Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circulation Research 66 2 (1990) 546-553
20. Morris G.S., Zhou Q., Wolf B.A., Christos S.C., DiDomenico D.F., Shug A.L., and Paulson D.J. Sodium pivalate reduces cardiac carnitine content and increases glucose oxidation without affecting cardiac functional capacity. Life Sciences 57 24 (1995) 2237-2244
21. Paulson D.J. Carnitine deficiency-induced cardiomyopathy. Molecular and Cellular Biochemistry 180 1-2 (1998) 33-41
22. Sesti C., Simkhovich B.Z., Kalvinsh I., and Kloner R.A. Mildronate a novel fatty acid oxidation inhibitor and antianginal agent reduces myocardial infarct size without affecting hemodynamics. Journal of Cardiovascular Pharmacology 47 3 (2006) 493-499
23. Simkhovich B.Z., Shutenko Z.V., Meirena D.V., Khagi K.B., Mezapuke R.J., Molodchina T.N., Kalvins I.J., and Lukevics E. 3-(222-Trimethylhydrazinium)propionate (THP)-a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochemical Pharmacology 37 2 (1988) 195-202
24. Spaniol M., Brooks H., Auer L., Zimmermann A., Solioz M., Stieger B., and Krahenbuhl S. Development and characterization of an animal model of carnitine deficiency. European Journal of Biochemistry 268 6 (2001) 1876-1887
25. Spaniol M., Kaufmann P., Beier K., Wuthrich J., Torok M., Scharnagl H., Marz W., and Krahenbuhl S. Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate. Journal of Lipid Research 44 1 (2003) 144-153
26. Stephens F.B., Constantin-Teodosiu D., and Greenhaff P.L. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. The Journal of Physiology 581 Pt 2 (2007) 431-444
27. Taegtmeyer H., McNulty P., and Young M.E. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 105 14 (2002) 1727-1733
28. Wang W., and Lopaschuk G.D. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Expert Review of Cardiovascular Therapy 5 6 (2007) 1123-1134
29. Youngren J.F. Regulation of insulin receptor function. Cellular and Molecular Life Sciences 64 7-8 (2007) 873-891